A new report predicts that the world market for cell-based assays will reach $4.7bn in 2016. That forecast and others appear in Cell-Based Assays: World Market Prospects 2013-2023, published in February 2013.
The new study explains how increased application and improvement in detection technology will be the major drivers for the cell-based assay market. As more pharma companies outsource drug discovery and development, forming strategic partnerships with contract research providers (CROs), cell-based assay services will increase their share of the market from 24.5% in 2011 to 30.2% in 2023, the report shows. In terms of application, primary screening accounted for the largest share of the cell-based assay market in 2011, with sales of $1.05bn (43.6%).
Hemant Mistry, a pharmaceutical industry analyst in visiongain, said: “Advances in detection equipment, improving sensitivity in drug screening, will act as key drivers for the cell-based assay market, in addition to the increased demand for more relevant and accurate toxicity models that can be used early in drug development. Miniaturising and multiplexing cell-based assays will make drug discovery more efficient and cheaper, which will also drive market growth over coming years.
“In 2011, developed markets – such as the US, Japan and Western Europe – accounted for the majority of the cell-based assays revenue. Global market shares for those countries are not expected to change significantly over the forecast period, as much of the world’s drug discovery and development occurs there. The US accounted for 44.0% of the market in 2011. Emerging markets, such as China and India, will also experience strong growth throughout the period 2013-2023, we predict. Growth will be driven by increased outsourcing and also the trend of major pharmaceutical companies moving R&D there.
“There are strong opportunities for the cell-based assays market to expand in line with the continued development of technology for miniaturisation and automation, which includes higher sensitivity detection systems. Furthermore, the increased emphasis on stem cells will help develop disease-relevant models, as well as an abundant supply of unmodified human cells. Greater use of label-free detection systems will also allow the use of unmodified cells, removing the need to insert reporter proteins that can affect cell function. Opportunities will also arise from trends within the pharmaceutical industry, such as the need for more-accurate toxicity data before clinical trials, and the greater demand for biological drugs. Those drug classes will increase demand for immunogenicity, comparative and neutralising antibody assays.”
Our report shows revenue forecasts to 2023 at world market, submarket and national level. It forecasts the following submarkets: